# Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

> **NCT02107872** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 55 (actual)

## Conditions studied

- Metabolic Disorders

## Interventions

- **DRUG:** REGN1500
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02107872
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2015-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02107872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02107872, "Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02107872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*